Brexit no-deal 'risk to supply of medicines'
Patients, including Theresa May, who rely on insulin, could be "seriously disadvantaged" in the event of a no-deal Brexit, the chairman of the UK's medicines regulator has warned.
Sir Michael Rawlins, of the Medicines and Healthcare Products Regulatory Agency (MHRA), said supplies of insulin and other medication which is not manufactured in the UK may be disrupted in such a scenario.
The Prime Minister, who has Type 1 diabetes, has previously said she regularly injects with insulin to manage the condition.
Sir Michael told the Pharmaceutical Journal: "We make no insulin in the UK. We import every drop of it.
"You can't transport insulin around ordinarily because it must be temperature-controlled."
Many diabetic people rely on insulin, Sir Michael said, "not least the Prime Minister".
He added: "Disruption to the supply chain is one of the ways that patients could be seriously disadvantaged."